Ly49 receptors are the canonical natural killer cell class-I major histocompatibility complex receptors expressed in mice. They have a well-defined role in natural killer cell self/non-self discrimination and in the developmental licensing of functional natural killer cells. In this thesis, I report two novel aspects of Ly49 receptor biology. First, I show that their expression may be regulated by specific nucleosome occupancy on AML-1 binding sites within the distal Ly49 promoter. This finding sheds light on a potential regulatory pathway that has thus far been unexplored in studies of the Ly49 receptor family, and highlights the Ly49 family as an ideal model system in which to study the impact of nucleosome occupancy in general. Second, I show that Ly49 receptors have a central and indispensable role in the emerging phenomenon known as adaptive natural killer cell memory. Natural killer cells have recently been observed displaying adaptive, long-lived, antigen specific memory responses comparable to T cell memory responses, but no explanatory mechanism has been discovered to describe how adaptive memory is possible in these ‘innate’ immune cells. Using Ly49-deficient mice, I show that the inhibitory, self-specific Ly49 receptors Ly49C and Ly49I are required for adaptive memory responses to chemical haptens or protein antigens. Moreover, I show that Ly49C/I binding capabilities are required during all stages of the memory response, as is antigen presentation in the context of class I major histocompatibility complex, again analogous to T cell memory responses. I present initial findings implicating these Ly49 receptors as key components of the antigen recognition process itself, and propose a mechanism based in evolutionarily ancient immunology to explain how this specificity could arise. Finally, I demonstrate that Ly49-dependent natural killer cell memory is capable of mediating powerful anti-cancer vaccination effects using an aggressive model of melanoma. Together, these findings in Ly49 family expression regulation and its functional role in adaptive NK cell responses open several new avenues of study in Ly49 receptor biology and natural killer cell immunology.

As células Natural Killer (NK), quando estimuladas por meio de seus receptores, rapidamente produzem citocinas e quimiocinas, incluindo IFN?, TNF?, TGF?, GMCSF, MIP1?, MIP1?, IL-10 e outras, as quais podem afetar a função de outras células hematopoéticas. Considerando as evidências recentes de que as célulastronco hematopoéticas (CTH) respondem diretamente à sinalização de várias citocinas, acreditamos que a produção de citocinas mediada pelas células NK possa regular a função da CTH e que a sua desregulação possa favorecer a transformação maligna. As neoplasias mieloproliferativas (NMP) negativas para o rearranjo t(9;22)/BCR-ABL1, incluindo as entidades Policitemia Vera (PV), Trombocitemia Essencial (TE) e Mielofibrose Primária (MFP), são doenças hematopoéticas originadas de alteração clonal da CTH, e podem servir de modelo para o estudo dessa regulação NK-CTH. Além de mutações que ativam vias de proliferação e sobrevivência celular, como a mutação JAK2V617F, presente em mais da metade das NMP, outros mecanismos contribuem para a patogênese e manutenção da doença, tais como mutações adicionais e regulação da hematopoese neoplásica pelo microambiente da medula óssea. Este último inclui não apenas células do estroma, mas também células do sistema imune. Dessa forma, com objetivo de investigar a potencial contribuição das células NK para a patogênese das NMP, caracterizamos células do sangue periférico de pacientes com NMP do Ambulatório de Hematologia do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, bem como células esplênicas obtidas de animais de um modelo murino condicional knockin de expressão heterozigótica da Jak2V617F (Jak2VF) quanto à frequência, expressão de receptores e função das células NK. Observamos menor porcentagem de células NK e maior expressão do receptor inibitório NKG2A nos animais Jak2 wt/VF. Pacientes portadores de NMP apresentaram número absoluto de células NK-CD16+ reduzido em relação aos controles saudáveis. O número de células NK-CD16+ foi menor na MFP em relação aos controles e à TE, particularmente naqueles portadores da mutação JAK2V617F. Encontramos menor expressão do receptor de ativação NKG2D nos portadores de PV positivos para a mutação JAK2V617F. Houve menor expressão do receptor de ativação NKp46 nos portadores de NMP, particularmente nos portadores da mutação JAK2V617F, e nos pacientes com MFP. Observamos também menor expressão do receptor NKG2A nos portadores de TE negativos para a mutação JAK2V617F. Em concordância com a redução de células NK, a porcentagem de linfócitos totais mostrou-se reduzida nos pacientes com NMP, particularmente nos portadores de MFP, independentemente da mutação JAK2V617F. Encontramos redução percentual e absoluta do subtipo de células NK CD56brightCD16- (cuja principal função é secretória) nos pacientes com NMP, especialmente na presença da mutação JAK2V617F, nos pacientes com PV e MFP, e menor frequência absoluta do subtipo CD56-CD16bright (com função primariamente citotóxica) nos portadores de MFP. Em contraste, não verificamos deficiência citotóxica das células NK dos animais Jak2 wt/VF em relação aos controles Jak2 wt/wt. Adicionalmente, as células NK dos animais Jak2-mutados demonstraram menor capacidade de secreção da citocina MIP-1?, reconhecida por regular a função de CTH, em relação aos animais controle. Finalmente, houve expressão significativamente aumentada do gene MyD88 nos animais mutados em relação aos controles, sugerindo que a via de sinalização dos receptores do tipo Toll (TLR) pode estar envolvida na regulação NKCTH nas NMP. Em resumo, detectamos deficiência numérica e funcional de células NK em células primárias murinas e humanas de NMP. Nossos achados sugerem potencial regulação da hematopoese maligna pelas células NK nestas neoplasias e podem contribuir para a identificação de novas estratégias terapêuticas que possam interferir nesta complexa interação. / Natural Killer (NK) cells, when stimulated by their receptors, rapidly produce cytokines and chemokines, including IFN?, TNF?, TGF?, GM-CSF, MIP1?, MIP1?, IL-10 and others, which may affect the function of other hematopoietic cells. Considering the recent evidence that hematopoietic stem cells (HSC) directly respond to cytokine signaling, we hypothesized that NK cells mediated cytokine production can regulate HSC function and that their dysregulation may favor malignant transformation. BCR-ABL1-negative myeloproliferative neoplasms (MPN), including Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF), are hematopoietic diseases originated from HSC clonal transformation, and thus can serve as a model for studying this NK-HSC regulation. In addition to mutations that activate cell proliferation and survival pathways, such as the JAK2V617F mutation, present in more than half of MPN cases, other mechanisms contribute to the pathogenesis and maintenance of the disease, such as additional mutations and regulation of neoplastic hematopoiesis by the bone marrow microenvironment. This latter includes not only stromal cells but also cells of the immune system. Therefore, in order to investigate the potential contribution of NK cells to the pathogenesis of MPN, we characterized the frequency, receptor expression and function of NK cells from patients with MPN from the Clinical Hospital of the Medical School of Ribeirão Preto, University of São Paulo, as well as from splenic cells obtained from animals of a conditional knockin murine model of Jak2V617F heterozigous expression. Lower percentage of NK cells and higher NKG2A inhibitory receptor expression was observed in Jak2 wt/VF animals as compared to Jak2 wt/wt controls. In agreement, patients with MPN presented reduced absolute numbers of NK-CD16+ cells when compared to healthy controls. The number of NKCD16+ cells was lower in the PMF than in controls or ET patients, particularly in those bearing the JAK2V617F mutation. We found lower expression of the NKG2D activatory receptor in PV patients with the JAK2V617F mutation. There was lower expression of the NKp46 activatory receptor in MPN patients, particularly in those with the JAK2V617F mutation, and in PMF patients. We also observed reduced expression of the NKG2A receptor in non-JAK2 mutated ET patients. In agreement with the NK cell reduction, the percentage of total lymphocytes was reduced in patients with MPN, particularly in PMF, regardless of the JAK2V617F mutation. We found an absolute decrease of the CD56brightCD16- NK subtype (whose main function is secretory) in patients with MPN, especially when the JAK2V617F mutation was present, in patients with PV and PMF. Also, lower absolute frequency of CD56-CD16bright NK subtype (primarily cytotoxic) was found in PMF patients. In contrast, we did not find cytotoxic deficiency in the Jak2 wt/VF NK cells as compared to the Jak2 wt/wt controls. In addition, Jak2-mutated NK cells presented reduced ability of secreting the cytokine MIP-1?, known to regulate HSC function. Finally, there was significantly increased expression of the MyD88 gene in the Jak2-mutated animals as compared to controls, suggesting that the Toll-like receptors (TLR) signaling pathway may be involved in NK-HSC regulation in MPN. In summary, we detected numerical and functional deficiency of NK cells in murine and human primary cells of MPN. Our findings suggest a potential regulation of malignant hematopoiesis by NK cells in these neoplasms and may contribute to the identification of new therapeutic strategies that may target this complex interaction.

Les cellules NK sont des lymphocytes de l'immunité innée impliqués dans la reconnaissance et l'élimination de cellules tumorales ou infectées par des pathogènes intracellulaires. La biologie des cellules NK est régulée par des facteurs intrinsèques comme les facteurs de transcription ainsi que par des facteurs environnementaux comme les cytokines, produites en condition homéostatique ou inflammatoire. Certaines cytokines, comme l'IL-15, l'IL-12 ou l'IL-18 sont connues pour potentialiser les fonctions effectrices des cellules NK. L'IL-15, en activant la voie STAT5 permet, d'une part, d'assurer la survie des cellules NK et, d'autre part via la kinase mTOR, d'induire leur prolifération, d'augmenter leur métabolisme ainsi que leurs fonctions effectrices. D'autres cytokines comme le TGF-ß sont connues pour inhiber les fonctions des cellules NK. Le TGF-ß1 est une des cytokines les plus immunosuppressives du système immunitaire et, en étant secrété´ par différents types de cancers, il participe a` l'échappement tumoral. Depuis longtemps, les effets du TGF-ß in vitro sont connus pour contrer ceux de l'IL-15. L'objectif de ce travail a été´ d'étudier les effets du TGF-ß sur la biologie des cellules NK. Nous avons observé´ que l'ajout de TGF-ß, in vitro, induit un blocage rapide de l'activation de la voie mTOR par l'IL-15, que le TGF-ß a des effets très proches de ceux de la rapamycine, un inhibiteur spécifique de mTOR et que, in vivo chez la souris, l'activation constitutive des voies de signalisation activées par le TGF-ß induit un phénotype proche de celui de la délétion de mTOR dans les cellules NK / NK cells are innate lymphocytes involved in the recognition and elimination of tumor or infected cells. The biology of NK cells is regulated by intrinsic factors such as transcription factors but also by cytokines produced at steady state or under inflammatory conditions. Some of these cytokines like IL-15, IL-12 or IL-18 are known to increase NK cells functions. IL-15 allows NK cell survival via STAT5 and, via mTOR, increase NK cell proliferation, metabolism and acquisition of functions. In the other hand, cytokines like TGF-ß are known to inhibit NK cell function. TGF-ß1 is a major immunosuppressive cytokine, often secreted by tumor cells and participates to tumor escape. The inhibitory effects of TGF-ß in vitro on IL-2/15 mediated NK cell activation have long been shown, but the mechanism remains unknown. The objective of this work was to characterize the effects of TGF-ß at a molecular level. We have observed that TGF-ß induces a rapid blockade of IL-15 induced mTOR activation, in vitro. TGF-ß and the mTOR inhibitor rapamycin have similar effects. Finally, using genetic mouse models in vivo, constitutive TGF-ß signaling or mTOR deletion results in similar developmental arrests in NK cells

Dans les pays occidentaux, les lymphomes T périphériques et NK représentent environ 10% des lymphomes non-Hodgkiniens. Le lymphome NK/T de type nasal est l'une des entités de présentation extra-ganglionnaire les plus fréquentes, en Asie, et en Amérique Centrale et du Sud. Il survient classiquement dans la sphère nasopharyngée avec une prédilection pour les adultes jeunes. Morphologiquement, la tumeur est souvent angiocentrique avec une invasion de la paroi des vaisseaux par les cellules tumorales d'aspect variable. Ces lymphomes ont le plus souvent une origine NK avec un phénotype CD3+ (cytoplasmique), CD5-, CD56+, CD4-/CD8-, expression des molécules cytotoxiques et absence de réarrangement des gènes des récepteurs T. Le virus d'Epstein-Barr est présent dans la quasi-totalité des cellules tumorales dans sa forme clonage épisomale, avec une latence de type II, suggérant son rôle dans l'oncogenèse. A côté des mutations fréquentes des gènes FAS et TP53 (p53) et des méthylations de TP73 et CDKN2A (p16), des délétions du bras long du chromosome 6q sont fréquemment observées. Très récemment, des méthylations et des mutations des gènes suppresseurs de tumeur PRDM1, ATG5, et AIM1 localisés en 6q21 ont été retrouvées dans les lignées de lymphome NK/T de type nasal. Nous avons réalisé une analyse combinée du profil d'expression génique et du profil génomique par hybridation comparative sur puces, d'échantillons tumoraux de lymphome NK/T de type nasal (n=9) et de lignées, comparés à celle de lymphocytes NK normaux et de lymphomes T périphériques, sans autre spécificité (PTCL, NOS). Nous avons identifié la signature moléculaire particulière du lymphome NK/T de type nasal caractérisée par un haut niveau des trascrits de marqueurs de cellules NK et de molécules cytotoxiques, notamment de granzyme H dans les lymphomes NK/T de type nasal comparé aux PTCL, NOS. Par immunohistochimie, nous avons validé l'expression "spécifique" de granzyme H par les cellules tumorales du lymphome NK/T de type nasal, qui pourrait constituer un nouveau marqueur de ces lymphomes. Comparé aux cellules NK normales, le lymphome NK/T de type nasal a une signature plus proche des cellules NK activées que des NK au repos et sur-expriment des gènes associés à la biologie vasculaire, des gènes induits par l'EBV, et PDGFRA. Nous avons confirmé l'expression protéique de PDGFRAa et de sa forme phosphorylée, et montré in vitro la sensibilité de la lignée tumorale MEC04 à l'imatinib mesytale. La dérégulation des voies de signalisation AKT, JAK-STAT et NF-kB, suggérée par les analyses bioinformatiques, a été corroborée par la mise en évidence d'une expression nucléaire des formes phosphorylées d'AKT, de STAT3 et de RelA dans les lymphomes NK/T de type nasal. De plus, plusieurs gènes dérégulés dans ces voies moléculaires sont localisés dans des régions altérées de manière récurrente par des gains ou des pertes (AKT3 (1q44), IL6R (1q21.3), CCL2 (17q12), TNFRSF21 (6p12.3)). En plus de l'activation constitutive de STAT3 confirmée par l'expression nucléaire de phospho-STAT3, l'inhibition de croissance et l'augmentation de la mort cellulaire des cellules de la lignée MEC04 résultant de l'inhibition de STAT3 conforte le rôle de STAT3 dan la lymphomagenèse du lymphome NK/T nasal. L'analyse intégrée a également mis en évidence la dérégulation du gène suppresseur de tumeur HACE1 en 6q21, confirmée par RT-PCR quantitative. Bien que les mécanismes exacts conduisant à l'activation de plusieurs voies moléculaires, de même qu'à la dérégultaion de HACE1 ne soient pas déterminés, nos résultats identifient plusieurs voies oncogéniques impliquées dans le lymphome NK/T de type nasal ainsi que de nouveaux biomarqueurs diagnostiques - comme granzyme H - et des cicles thérapeutiques d'intérêt. L'étude en cours du profil d'expression des microARNs pourrait apporter un éclairage sur les mécanismes impliqués dans certaines voies identifiées / In Western countries, mature natural killer (NK)- and T-cell lymphomas account for 15% to 20% of aggressive lymphomas and around 10 % of all non-Hodgkin lymphomas. This number is higher in Asia, with 25% in Japan and 39% in Taiwan. Among those T- and NK-cell lymphomas with primary extranodal presentation, extranodal NK/T-cell lymphoma of nasal type (nasal NKTCL) is one of the most common entities in Asian, Central and South American populations. It classically arises in the nasal region showing a predilection for young adults with male predominance. This tumor morphologically exhibits an angiocentric and angio destructive growth pattern, admixed with polymorphous non-neoplastic infiltrates. Most tumor cells have a cytoplasmic CD3+, CD5-, CD56+, CD4-/CD8- phenotype with expression of cytotoxic granule-associated proteins and without rearrangement of T-cell receptors genes. Killer immunoglobulin-like receptors have been reproted to be expressed in a subset of this lymphoma and its expression might be associated with prognosis. Epstein-Barr virus is present in virtually all neoplastic cells in its clonal episomal form with type II latency program, implying a role in oncogenesis. Although the results were variable between different studies, methylations of TP73 (p73) and CDKN2A (p16) and mutations of FAS and TP53 (p53) were frequently found in nasal NKTCL. Genomic alterations have also been reported in nasal NKTCL with frequent deletion in chromosome 6q. A very recent study also identified both methylations and mutations of three putative tumor suppressor genes PRDM, ATG5, and AIM1 mapping to del6q21 in nasal NKTCL cell times. We performed integrative gene expression profiling and array-based comparative genomic hybridization analyses of nasal NKTCL tumors as well as tumour-derived cell lines, compared to that of normal NK cells and peripheral T-cell lymphomas, not otherwise specified (PTCL, NOS). We identified the distinctive molecular signature of nasal NKTCL with high transcript levels for NK-cell markers ans cytotoxic molecules, especially granzyme H in nasal NKTCL compared to PTCL, NOS. By immunohistochemistry, we validated expression of grnzyme H which appears a novel sensitive biomarker of nasal NKTCL. Compared to normal NK cells, nasal NKTCL tumors were closer to activated than resting cells and overexpressed several genes related to vascular biology, EBV-induced genes and PDGFRA. Notably, we confirmed the expression of PDGFRa and its phosphorylated form at the protein level, and in vitro the MEC04, nasal NKTCL-cell line, was sensitive to imatinib mesylate. Deregulation of the AKT, JAK-STAT and NF-kB pathways suggested by bioinformatical analysis, was corroborated by nuclear expression of phosphorylated AKT, STAT3 and RelA in nasal NKTCL, and several deregulated genes in these pathways mapped to regions of recurrent copy number aberrations (AKT3 (1q44), IL6R (1q21.3), CCL2 (17q12), TNFRSF21 (6p12.3)). In addition to constitutive activation of STAT3 as confirmed by the demonstration of phosphorylated STAT3 in the nuclei of neoplastic nasal NKTCL cells, growth inhibition and cell death of nasal NKTCL cells induced by STAT3 inhibition implied the role of STAT3 in the nasal NK/T-cell lymphomagenesis. Integrative analysis and qRT-PCR analysis also evidenced deregulation of another tumor suppressor HACE1 in the frequently deleed 6q21 region. Although the exact mechanism of activation of several pathways as well as that of HACE1 deregulation remains to be determined, our studies highlight emerging oncogenic pathways in nasal NKTCL and identify novel diagnostic and therapeutic targets. The ongoing investigation of microRNA expression profiling might shed light in a better understanding of the pathogenesis of nasal NKTCL and especially of the activation of oncogenic pathways. Connectivity map analysis may also help to depict other targeted therapies useful to improve the prognosis of this agressive lymphoma

As células Natural Killer (NK), quando estimuladas por meio de seus receptores, rapidamente produzem citocinas e quimiocinas, incluindo IFN?, TNF?, TGF?, GMCSF, MIP1?, MIP1?, IL-10 e outras, as quais podem afetar a função de outras células hematopoéticas. Considerando as evidências recentes de que as célulastronco hematopoéticas (CTH) respondem diretamente à sinalização de várias citocinas, acreditamos que a produção de citocinas mediada pelas células NK possa regular a função da CTH e que a sua desregulação possa favorecer a transformação maligna. As neoplasias mieloproliferativas (NMP) negativas para o rearranjo t(9;22)/BCR-ABL1, incluindo as entidades Policitemia Vera (PV), Trombocitemia Essencial (TE) e Mielofibrose Primária (MFP), são doenças hematopoéticas originadas de alteração clonal da CTH, e podem servir de modelo para o estudo dessa regulação NK-CTH. Além de mutações que ativam vias de proliferação e sobrevivência celular, como a mutação JAK2V617F, presente em mais da metade das NMP, outros mecanismos contribuem para a patogênese e manutenção da doença, tais como mutações adicionais e regulação da hematopoese neoplásica pelo microambiente da medula óssea. Este último inclui não apenas células do estroma, mas também células do sistema imune. Dessa forma, com objetivo de investigar a potencial contribuição das células NK para a patogênese das NMP, caracterizamos células do sangue periférico de pacientes com NMP do Ambulatório de Hematologia do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, bem como células esplênicas obtidas de animais de um modelo murino condicional knockin de expressão heterozigótica da Jak2V617F (Jak2VF) quanto à frequência, expressão de receptores e função das células NK. Observamos menor porcentagem de células NK e maior expressão do receptor inibitório NKG2A nos animais Jak2 wt/VF. Pacientes portadores de NMP apresentaram número absoluto de células NK-CD16+ reduzido em relação aos controles saudáveis. O número de células NK-CD16+ foi menor na MFP em relação aos controles e à TE, particularmente naqueles portadores da mutação JAK2V617F. Encontramos menor expressão do receptor de ativação NKG2D nos portadores de PV positivos para a mutação JAK2V617F. Houve menor expressão do receptor de ativação NKp46 nos portadores de NMP, particularmente nos portadores da mutação JAK2V617F, e nos pacientes com MFP. Observamos também menor expressão do receptor NKG2A nos portadores de TE negativos para a mutação JAK2V617F. Em concordância com a redução de células NK, a porcentagem de linfócitos totais mostrou-se reduzida nos pacientes com NMP, particularmente nos portadores de MFP, independentemente da mutação JAK2V617F. Encontramos redução percentual e absoluta do subtipo de células NK CD56brightCD16- (cuja principal função é secretória) nos pacientes com NMP, especialmente na presença da mutação JAK2V617F, nos pacientes com PV e MFP, e menor frequência absoluta do subtipo CD56-CD16bright (com função primariamente citotóxica) nos portadores de MFP. Em contraste, não verificamos deficiência citotóxica das células NK dos animais Jak2 wt/VF em relação aos controles Jak2 wt/wt. Adicionalmente, as células NK dos animais Jak2-mutados demonstraram menor capacidade de secreção da citocina MIP-1?, reconhecida por regular a função de CTH, em relação aos animais controle. Finalmente, houve expressão significativamente aumentada do gene MyD88 nos animais mutados em relação aos controles, sugerindo que a via de sinalização dos receptores do tipo Toll (TLR) pode estar envolvida na regulação NKCTH nas NMP. Em resumo, detectamos deficiência numérica e funcional de células NK em células primárias murinas e humanas de NMP. Nossos achados sugerem potencial regulação da hematopoese maligna pelas células NK nestas neoplasias e podem contribuir para a identificação de novas estratégias terapêuticas que possam interferir nesta complexa interação. / Natural Killer (NK) cells, when stimulated by their receptors, rapidly produce cytokines and chemokines, including IFN?, TNF?, TGF?, GM-CSF, MIP1?, MIP1?, IL-10 and others, which may affect the function of other hematopoietic cells. Considering the recent evidence that hematopoietic stem cells (HSC) directly respond to cytokine signaling, we hypothesized that NK cells mediated cytokine production can regulate HSC function and that their dysregulation may favor malignant transformation. BCR-ABL1-negative myeloproliferative neoplasms (MPN), including Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF), are hematopoietic diseases originated from HSC clonal transformation, and thus can serve as a model for studying this NK-HSC regulation. In addition to mutations that activate cell proliferation and survival pathways, such as the JAK2V617F mutation, present in more than half of MPN cases, other mechanisms contribute to the pathogenesis and maintenance of the disease, such as additional mutations and regulation of neoplastic hematopoiesis by the bone marrow microenvironment. This latter includes not only stromal cells but also cells of the immune system. Therefore, in order to investigate the potential contribution of NK cells to the pathogenesis of MPN, we characterized the frequency, receptor expression and function of NK cells from patients with MPN from the Clinical Hospital of the Medical School of Ribeirão Preto, University of São Paulo, as well as from splenic cells obtained from animals of a conditional knockin murine model of Jak2V617F heterozigous expression. Lower percentage of NK cells and higher NKG2A inhibitory receptor expression was observed in Jak2 wt/VF animals as compared to Jak2 wt/wt controls. In agreement, patients with MPN presented reduced absolute numbers of NK-CD16+ cells when compared to healthy controls. The number of NKCD16+ cells was lower in the PMF than in controls or ET patients, particularly in those bearing the JAK2V617F mutation. We found lower expression of the NKG2D activatory receptor in PV patients with the JAK2V617F mutation. There was lower expression of the NKp46 activatory receptor in MPN patients, particularly in those with the JAK2V617F mutation, and in PMF patients. We also observed reduced expression of the NKG2A receptor in non-JAK2 mutated ET patients. In agreement with the NK cell reduction, the percentage of total lymphocytes was reduced in patients with MPN, particularly in PMF, regardless of the JAK2V617F mutation. We found an absolute decrease of the CD56brightCD16- NK subtype (whose main function is secretory) in patients with MPN, especially when the JAK2V617F mutation was present, in patients with PV and PMF. Also, lower absolute frequency of CD56-CD16bright NK subtype (primarily cytotoxic) was found in PMF patients. In contrast, we did not find cytotoxic deficiency in the Jak2 wt/VF NK cells as compared to the Jak2 wt/wt controls. In addition, Jak2-mutated NK cells presented reduced ability of secreting the cytokine MIP-1?, known to regulate HSC function. Finally, there was significantly increased expression of the MyD88 gene in the Jak2-mutated animals as compared to controls, suggesting that the Toll-like receptors (TLR) signaling pathway may be involved in NK-HSC regulation in MPN. In summary, we detected numerical and functional deficiency of NK cells in murine and human primary cells of MPN. Our findings suggest a potential regulation of malignant hematopoiesis by NK cells in these neoplasms and may contribute to the identification of new therapeutic strategies that may target this complex interaction.

Marathon runners (N = 22) who had completed at least seven marathons (X ± SEM = 23.6 ± 5.7) and had been training for marathon race events for at least 4 yr (12.3 ± 1.3) were compared with sedentary controls (N = 18). Although the two groups were of similar age (38.7 ± 1.5 and 43.9 ± 2.2 yr, respectively) and height, the marathon runners were significantly leaner and possessed a VO2max 60% higher than that of the controls. Neutrophil counts tended to be lower in the group of marathoners, while other leukocyte and lymphocyte subsets were similar to controls. Mitogen-induced lymphocyte proliferation did not differ between groups. Natural killer cell cyto-toxic activity (NKCA) was significantly higher in the marathoners versus controls (373 ± 38 vs 237 ± 41 total lytic units, respectively, a 57% difference, P = 0.02). For all subjects combined (N = 40) and within the group of marathon runners (N — 22), percent body fat was negatively correlated with NKCA (r = -0.48, P = 0.002; r = -0.49, P = 0.019, respectively), and age was negatively correlated with Con A-induccd lymphocyte proliferation (r = -0.41, P = 0.009; r = -0.53, P = 0.011, respectively). These data indicate that NKCA but not mitogen-induced lymphocyte proliferation is higher in marathon runners relative to sedentary controls.

No description available.

Natural killer (NK) cells are lymphocytes of the innate immune system that play a major role in the destruction of both tumours and virally-infected cells. The cytotoxicity of NK cells is tightly controlled by signals received through activating and inhibitory receptors. NK cells express a variety of inhibitory receptors such as Ly49 receptors. Ly49 receptors bind to class I MHC molecules that expressed on normal cells. Using Ly49-deficient (NKCKD) mice we show that Ly49-KD NK cells successfully recognize and kill influenza virus-infected cells and that NKCKD mice exhibit better survival than wild-type mice. Moreover, influenza virus infection has a propensity to upregulate cell surface expression of MHC-I on murine lung epithelial cells in vivo. Significantly, we demonstrate increased lung damage of WT-mice versus NKCKD mice after influenza virus infection as determined by histological analyses. This data indicated that absence of Ly49 inhibitory NK receptors greatly enhances survival of infected mice.

Influenza A virus (IAV) infection is a highly contagious respiratory disease, which can cause substantial morbidity and occasionally death. Invariant natural killer T (iNKT) cells, a subset of CD1d-restricted T lymphocytes, have been identified as important modulators of immunity, mediating both pro- and anti-inflammatory responses. We show that iNKTs play an important role for the generation of protective innate and adaptive immune responses to IAV, and enhance heterotypic immunity to influenza virus following vaccination with a novel pseudotyped virus, S-FLU, which lacks HA expression. iNKT-deficient mice (Jα18^-/-) showed increased susceptibility and lung pathology following IAV infection, which correlated with an exaggerated accumulation of inflammatory monocytes and neutrophils in the lung. Consistent with these findings, we demonstrated in IAV-infected CD1d^-/-:CD1d^{+/+} mixed bone marrow chimeric mice, that the lack of CD1d expression on myeloid cells purified from the lungs of IAV-infected mice significantly increased expression of genes linked to cell activation, survival and polarisation between pro- and antiinflammatory responses. We extended these results by examining the role of chemokine signalling during IAV infection, and identified a novel role for fractalkine (CX3CL1) and its receptor (CX3CR1) in innate immune cell recruitment. The use of CX3CR1-iNKT cell double knockout mice revealed that, although upregulated in Jα18^-/- mice, CX3CR1-CX3CL1 signalling is not required for cell migration during exacerbated IAV-responses. Finally, we showed that iNKT-deficient mice displayed reduced longevity of peripheral IAVspecific CD8^+ T cells following S-FLU vaccination, compared with wild-type mice. S-FLU vaccination protected mice following 5 day heterotypic challenge, however vaccinated mice exhibited reduced viral clearance, and importantly a significant reduction in IAV specific memory T cell response, suggesting a possible role of iNKT cells during T cell priming in modulating the lifespan of antigen-specific T cell responses. Although additional experiments are warranted, these results suggest that harnessing iNKT cells should be considered to modulate the innate and adaptive immune response to optimise heterotypic vaccine design and for therapeutic intervention against acute influenza infection.

Danazol, um andrógeno sintético, desenvolvido em 1970 para o tratamento da endometriose, tem aplicação controvérsia no pré-tratamento de mulheres com infertilidade sem causa aparente, abortos recorrentes e que seriam submetidas à fertilização com transferência de embrião. O conhecimento sobre a atuação deste medicamento sobre a incidência de células uNK, morfologia uterina e funções cognitivas após sua administração ainda são muito fragmentados e não conclusivos. Os objetivos deste trabalho foram avaliar os efeitos das diferentes concentrações do danazol no comportamento de camundongos prenhes, bem como, as possíveis alterações na implantação, viabilidade, perda embrionára, morfologia do útero e incidência dos subtipos de células uNK reativos para lectina DBA. Foram utilizadas noventa e três fêmeas da linhagem Swiss, obtidas do Biotério da Universidade Federal de Alfenas, tratadas durante 14 dias por meio de gavagem com água destilada + tween 1% (grupo controle) e com água destilada + tween 1% + danazol nas concentrações de 0,75; 7,5; ou 75 mg/kg. O tratamento nos animais foi suspenso por 4 dias e após este prazo as fêmeas foram acasaladas com os machos. O dia em que foi constatada a presença do tampão vaginal foi considerado o 1° dia de gestação. Os testes comportamentais foram realizados e os animais foram sacrificados no 6º, 8º, 10º, 12º e 15º dia de gestação (ddg). Os resultados obtidos mostraram que danazol na dosagem de 0,75 mg/Kg apresentou efeito ansiogênico em camundongos e diminuiu a retenção de memória de curto prazo no 10º ddg. Na concentração de 7,5 mg/Kg provocou aumento da retenção de memória a curto prazo e estado equivalente ao depressivo. A diminuição do tempo de exploração global, à medida que a concentração do hormônio foi aumentada sugere efeito dose dependente de danazol no estabelecimento de estado de sonolência e apatia em camundongos no 10º ddg. Danazol provocou atraso no período para sucesso da cópula, no entanto, aumentou a taxa de prenhez sem reduzir o número de corpus lúteos em todas as dosagens utilizadas. Nos camundongos tratados com a dosagem 7,5 mg/Kg de danazol foram observadas, a partir do 10º ddg, muitas células grandes e de morfologia equivalente às células trofoblásticas gigantes ao redor dos vasos que nutrem a decídua e o embrião, o que sugere que está droga aumenta a invasividade do trofoblasto a partir do período médio da prenhez. Danazol na concentração de 7,5 mg/Kg provocou aumento no número de células uNK, enquanto dosagens menores (0,75 mg/Kg) e maiores (75 mg/Kg) causaram diminuição neste número, demonstrando o efeito dose dependente de danazol no número de células uNK. A análise dos diferentes subtipos de uNK no útero mostrou que danazol aumenta a migração destas células, podendo prejudicar a proliferação celular em doses elevadas e acelerar a diferenciação celular em áreas próximas ao embrião. As maiores alterações relacionadas à ansiedade e memória observadas no 10º ddg, associadas às alterações morfológicas nos sítios de implantação embrionária e aumento na proliferação de células natural killer uterinas também neste período, demonstram a integração entre sistemas nervoso, endócrino e imunológico durante a prenhez e a ação dose-dependente de danazol modulando as respostas destes sistemas. / Danazol, a synthetic androgen, developed in 1970 for the treatment of endometriosis, has a controversial application on the pre-treatment of women with unexplained infertility, recurrent miscarriage, and the ones that would undergo fertilization with embryo transfer. The knowledge about the way this compound works after its administration on the incidence of uNK cells, uterine morphology and cognitive functions is still incomplete and inconclusive. Our objectives were to evaluate the effects of different concentrations of danazol on the behavior of pregnant mice, as well as possible changes in implantation, viability, embryonic loss, morphology of the uterus and the incidence of DBA lectin-reactive uNK cell subtype. Ninety-three Swiss female mice from Universidade Federal de Alfenas vivarium were treated for 14 days by gavage with either distilled water + 1% Tween (control) or distilled water + 1% Tween + 0.75, 7.5 or 75 mg/kg of danazol. Females were mated with males after suspension of treatment during four days. Day 1 of gestation was established as the day when the presence of vaginal plug was detected. Behavioral tests were performed and the animals were sacrificed at 6th, 8th, 10th, 12th and 15th gestation days (gd). The data showed that 0.75 mg/kg of danazol caused an anxiogenic effect on mice and decreased the retention of short-term memory in the 10th gd. 7.5 mg/kg of this drug increased the retention of short-term memory and developed a depression-like state on the animals. The fact that gradual increase on hormone concentration caused gradual decrease on the global exploration time suggests a dose-dependent effect of danazol on establishing a state of somnolence and apathy in mice in the 10th ddg. Danazol caused a delay on time of successful mating, however, it increased the rate of pregnancy without reducing the number of corpus luteum in all dosages used. In mice treated with 7.5 mg/kg of danazol, many large cells with a trophoblast-like morphology were observed around vessels that nourish the decidua and the embryo starting at 10th gd, what suggests that this drug increases the invasiveness of the trophoblast starting in the middle period of pregnancy. 7.5 mg/kg of danazol increased the number of uNK cells, whereas the lowest (0.75 mg/ kg) and the highest (75 mg / kg) doses caused a decrease in this number, demonstrating a dose dependent effect of danazol on the number of uNK cells. The analysis of different subtypes of uNK cells in the uterus showed that danazol increases the migration of these cells and can also impair cell proliferation on higher doses. It also suggests that danazol can stimulate cell differentiation in areas close to the embryo. The major changes related to anxiety and memory observed in the 10th gd, associated with morphological changes in the sites of embryo implantation and increase in proliferation of uterine natural killer cells in this period, demonstrate the integration between the nervous, endocrine and immune systems during pregnancy and the dose-dependent action of danazol in the modulation of these systems. / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPES